Monday, May 17, 2021

Reminder: Provide Clear Instructions to Patients Who Self-Collect an Anterior Nares Nasal Samples

Without proper instructions, patients may not collect enough sample for SARS-CoV-2 testing

If your email program has trouble displaying this email, view as a webpage.

FDA - Center for Devices and Radiological Health

Reminder: Provide Clear Instructions to Patients Who Self-Collect an Anterior Nares (Nasal) Sample: Letter to Health Care Providers 

The U.S. Food and Drug Administration (FDA) reminds health care providers to give clear, step-by-step instructions to patients who, in a health care setting, self-collect anterior nasal samples for SARS-CoV-2 testing. Without proper instructions, patients may not collect an adequate sample for testing, which may decrease the sensitivity of the test. 

Read More

The Letter to Health Care Providers includes: 

  • Details for providing patients with clear instructions for performing anterior nares (nasal) sample self-collection in a health care setting.
  • Recommendations for health care providers.
  • Suggested resources on testing for SARS-CoV-2.
  • Instructions for reporting problems with SARS-CoV-2 testing.

Questions?

If you have questions about this Letter to Health Care Providers, email COVID19DX@fda.hhs.gov.


This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration · 
10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA
GovDelivery logo

No comments:

Post a Comment